Adriana Weinberg
Concepts (834)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 101 | 2026 | 3189 | 10.050 |
Why?
| | Herpes Zoster Vaccine | 26 | 2026 | 154 | 9.910 |
Why?
| | Herpes Zoster | 33 | 2025 | 318 | 9.140 |
Why?
| | Herpesvirus 3, Human | 37 | 2025 | 341 | 7.230 |
Why?
| | Influenza Vaccines | 29 | 2021 | 533 | 5.840 |
Why?
| | Cytomegalovirus Infections | 28 | 2024 | 206 | 5.790 |
Why?
| | Immunity, Cellular | 34 | 2025 | 273 | 5.560 |
Why?
| | Antibodies, Viral | 44 | 2024 | 673 | 5.200 |
Why?
| | Pregnancy Complications, Infectious | 27 | 2026 | 437 | 5.090 |
Why?
| | T-Lymphocytes, Regulatory | 15 | 2025 | 407 | 4.560 |
Why?
| | Cytomegalovirus | 27 | 2024 | 168 | 4.210 |
Why?
| | Influenza, Human | 27 | 2021 | 623 | 3.910 |
Why?
| | Respiratory Syncytial Virus, Human | 7 | 2026 | 81 | 3.340 |
Why?
| | Antiretroviral Therapy, Highly Active | 22 | 2017 | 279 | 2.780 |
Why?
| | Immunologic Memory | 15 | 2026 | 368 | 2.560 |
Why?
| | Influenza A Virus, H1N1 Subtype | 13 | 2021 | 158 | 2.510 |
Why?
| | Pneumococcal Infections | 4 | 2022 | 103 | 2.480 |
Why?
| | Vaccines, Attenuated | 23 | 2024 | 129 | 2.470 |
Why?
| | Anti-HIV Agents | 19 | 2026 | 908 | 2.450 |
Why?
| | T-Lymphocyte Subsets | 12 | 2019 | 418 | 2.440 |
Why?
| | T-Lymphocytes | 22 | 2020 | 1996 | 2.380 |
Why?
| | Leukocytes, Mononuclear | 16 | 2025 | 573 | 2.260 |
Why?
| | CD4-Positive T-Lymphocytes | 29 | 2023 | 1138 | 2.050 |
Why?
| | Respiratory Tract Infections | 7 | 2025 | 395 | 2.030 |
Why?
| | Respiratory Syncytial Virus Infections | 3 | 2026 | 139 | 1.960 |
Why?
| | Isoniazid | 7 | 2026 | 71 | 1.680 |
Why?
| | Vaccination | 23 | 2024 | 1423 | 1.660 |
Why?
| | Chickenpox | 8 | 2024 | 82 | 1.600 |
Why?
| | Humans | 241 | 2026 | 145491 | 1.570 |
Why?
| | Antiviral Agents | 17 | 2023 | 772 | 1.530 |
Why?
| | Latent Tuberculosis | 2 | 2026 | 71 | 1.520 |
Why?
| | Chickenpox Vaccine | 11 | 2024 | 75 | 1.520 |
Why?
| | Interferon-gamma | 20 | 2022 | 782 | 1.520 |
Why?
| | Tuberculosis | 7 | 2026 | 292 | 1.490 |
Why?
| | Pregnancy | 46 | 2026 | 7197 | 1.470 |
Why?
| | Female | 167 | 2026 | 78763 | 1.450 |
Why?
| | Drug Resistance, Viral | 14 | 2017 | 124 | 1.410 |
Why?
| | HIV | 8 | 2022 | 252 | 1.390 |
Why?
| | CD8-Positive T-Lymphocytes | 12 | 2019 | 917 | 1.330 |
Why?
| | Virus Diseases | 4 | 2018 | 218 | 1.320 |
Why?
| | Antitubercular Agents | 5 | 2026 | 216 | 1.320 |
Why?
| | Infant | 44 | 2026 | 10064 | 1.300 |
Why?
| | DNA, Viral | 13 | 2024 | 357 | 1.290 |
Why?
| | Tetanus Toxoid | 4 | 2021 | 34 | 1.270 |
Why?
| | Mycobacterium tuberculosis | 2 | 2026 | 339 | 1.260 |
Why?
| | Virus Shedding | 6 | 2017 | 48 | 1.240 |
Why?
| | Infectious Disease Transmission, Vertical | 10 | 2023 | 194 | 1.210 |
Why?
| | Adult | 103 | 2026 | 40707 | 1.200 |
Why?
| | Influenza A virus | 9 | 2013 | 117 | 1.170 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 7 | 9 | 2009 | 28 | 1.160 |
Why?
| | Vaccines, Synthetic | 8 | 2026 | 138 | 1.160 |
Why?
| | Influenza B virus | 9 | 2017 | 47 | 1.150 |
Why?
| | Hepatitis A Vaccines | 5 | 2020 | 19 | 1.120 |
Why?
| | Antibodies, Bacterial | 5 | 2022 | 147 | 1.110 |
Why?
| | Dermatitis, Atopic | 5 | 2020 | 323 | 1.080 |
Why?
| | Male | 127 | 2026 | 72817 | 1.080 |
Why?
| | B-Lymphocytes | 7 | 2021 | 878 | 1.060 |
Why?
| | Cord Blood Stem Cell Transplantation | 3 | 2023 | 103 | 1.060 |
Why?
| | Adjuvants, Immunologic | 8 | 2021 | 246 | 1.050 |
Why?
| | CD4 Lymphocyte Count | 17 | 2019 | 280 | 0.990 |
Why?
| | HIV-1 | 13 | 2019 | 905 | 0.990 |
Why?
| | Antibody Formation | 7 | 2023 | 291 | 0.980 |
Why?
| | Hemagglutination Inhibition Tests | 14 | 2021 | 38 | 0.970 |
Why?
| | Infant, Newborn | 26 | 2026 | 6437 | 0.960 |
Why?
| | Pneumococcal Vaccines | 3 | 2022 | 129 | 0.960 |
Why?
| | Anti-Retroviral Agents | 8 | 2023 | 251 | 0.940 |
Why?
| | Transforming Growth Factor beta | 4 | 2025 | 475 | 0.940 |
Why?
| | Lymphocyte Activation | 26 | 2020 | 1134 | 0.940 |
Why?
| | Breast Feeding | 4 | 2023 | 447 | 0.910 |
Why?
| | Transforming Growth Factor beta1 | 2 | 2025 | 176 | 0.910 |
Why?
| | Gastrointestinal Microbiome | 2 | 2025 | 774 | 0.910 |
Why?
| | Interleukin-2 | 13 | 2022 | 440 | 0.890 |
Why?
| | Monocytes | 2 | 2025 | 536 | 0.870 |
Why?
| | Vaccines, Inactivated | 10 | 2017 | 70 | 0.870 |
Why?
| | Respiratory Syncytial Viruses | 1 | 2025 | 58 | 0.860 |
Why?
| | Enzyme-Linked Immunospot Assay | 6 | 2018 | 37 | 0.860 |
Why?
| | Viral Load | 18 | 2023 | 528 | 0.840 |
Why?
| | Viremia | 9 | 2021 | 160 | 0.840 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2023 | 700 | 0.840 |
Why?
| | HIV Protease Inhibitors | 3 | 2019 | 69 | 0.810 |
Why?
| | Child, Preschool | 35 | 2025 | 11837 | 0.790 |
Why?
| | Immune Reconstitution | 1 | 2023 | 10 | 0.790 |
Why?
| | Child | 54 | 2025 | 22680 | 0.780 |
Why?
| | Epstein-Barr Virus Infections | 5 | 2013 | 102 | 0.780 |
Why?
| | Environmental Exposure | 2 | 2018 | 577 | 0.750 |
Why?
| | Papillomavirus Vaccines | 3 | 2018 | 296 | 0.750 |
Why?
| | Double-Blind Method | 18 | 2026 | 2060 | 0.740 |
Why?
| | Cytokines | 13 | 2026 | 2054 | 0.740 |
Why?
| | Receptors, Tumor Necrosis Factor | 8 | 2001 | 161 | 0.720 |
Why?
| | Herpesvirus 1, Human | 3 | 2016 | 84 | 0.710 |
Why?
| | Adolescent | 54 | 2025 | 22485 | 0.700 |
Why?
| | Polymerase Chain Reaction | 12 | 2023 | 1049 | 0.680 |
Why?
| | Orthomyxoviridae | 3 | 2017 | 40 | 0.680 |
Why?
| | Middle Aged | 64 | 2026 | 36176 | 0.680 |
Why?
| | Young Adult | 30 | 2026 | 14192 | 0.670 |
Why?
| | Aged | 43 | 2026 | 26125 | 0.650 |
Why?
| | DNA-Directed DNA Polymerase | 4 | 2008 | 48 | 0.640 |
Why?
| | Vitamin D | 2 | 2024 | 403 | 0.630 |
Why?
| | Aged, 80 and over | 18 | 2022 | 8326 | 0.620 |
Why?
| | Viral Proteins | 5 | 2012 | 353 | 0.620 |
Why?
| | Rotavirus Infections | 2 | 2017 | 37 | 0.620 |
Why?
| | Rotavirus Vaccines | 2 | 2017 | 39 | 0.620 |
Why?
| | Postpartum Period | 7 | 2026 | 373 | 0.610 |
Why?
| | Herpesvirus 4, Human | 8 | 2014 | 177 | 0.610 |
Why?
| | Immunosuppressive Agents | 7 | 2014 | 842 | 0.600 |
Why?
| | Killer Cells, Natural | 5 | 2026 | 480 | 0.600 |
Why?
| | Viral Envelope Proteins | 2 | 2021 | 98 | 0.590 |
Why?
| | Medroxyprogesterone Acetate | 2 | 2016 | 33 | 0.580 |
Why?
| | Respiratory Syncytial Virus Vaccines | 1 | 2019 | 39 | 0.570 |
Why?
| | Inflammation | 5 | 2026 | 2883 | 0.570 |
Why?
| | RNA, Viral | 9 | 2024 | 693 | 0.560 |
Why?
| | Antibodies, Neutralizing | 7 | 2021 | 342 | 0.560 |
Why?
| | Paramyxoviridae Infections | 2 | 2011 | 12 | 0.560 |
Why?
| | Simplexvirus | 9 | 2016 | 82 | 0.550 |
Why?
| | Human papillomavirus 18 | 1 | 2018 | 12 | 0.550 |
Why?
| | Immunocompromised Host | 9 | 2019 | 202 | 0.550 |
Why?
| | Human papillomavirus 16 | 1 | 2018 | 27 | 0.540 |
Why?
| | Hepatitis A Antibodies | 2 | 2009 | 3 | 0.540 |
Why?
| | Cryopreservation | 2 | 2010 | 109 | 0.540 |
Why?
| | AIDS-Related Opportunistic Infections | 3 | 2019 | 130 | 0.530 |
Why?
| | Th1 Cells | 1 | 2018 | 139 | 0.530 |
Why?
| | Lymphocyte Subsets | 2 | 2015 | 79 | 0.520 |
Why?
| | Flow Cytometry | 11 | 2019 | 1156 | 0.510 |
Why?
| | Antigens, Viral | 8 | 2017 | 182 | 0.510 |
Why?
| | Immunization, Secondary | 6 | 2017 | 92 | 0.500 |
Why?
| | Immunoconjugates | 2 | 2013 | 138 | 0.500 |
Why?
| | Age Factors | 9 | 2019 | 3340 | 0.500 |
Why?
| | Immunity, Innate | 3 | 2026 | 846 | 0.500 |
Why?
| | Mutation | 7 | 2009 | 4093 | 0.490 |
Why?
| | Hospitalization | 6 | 2021 | 2458 | 0.490 |
Why?
| | Acyclovir | 6 | 2012 | 97 | 0.490 |
Why?
| | Herpesviridae Infections | 5 | 2013 | 149 | 0.480 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 5 | 1999 | 70 | 0.480 |
Why?
| | Premature Birth | 2 | 2019 | 387 | 0.470 |
Why?
| | Case-Control Studies | 14 | 2024 | 3619 | 0.470 |
Why?
| | Host-Pathogen Interactions | 1 | 2019 | 369 | 0.470 |
Why?
| | Immunoglobulin G | 8 | 2026 | 890 | 0.470 |
Why?
| | Viral Vaccines | 4 | 2014 | 108 | 0.460 |
Why?
| | Herpes Simplex | 4 | 2016 | 98 | 0.450 |
Why?
| | T-Lymphocytes, Cytotoxic | 3 | 2011 | 177 | 0.450 |
Why?
| | Reagent Kits, Diagnostic | 2 | 2005 | 34 | 0.440 |
Why?
| | Contraceptive Agents, Female | 1 | 2016 | 80 | 0.430 |
Why?
| | Central Nervous System Viral Diseases | 3 | 2004 | 78 | 0.430 |
Why?
| | B-Lymphocyte Subsets | 1 | 2015 | 79 | 0.420 |
Why?
| | Immunoassay | 5 | 2017 | 108 | 0.420 |
Why?
| | Immunity, Mucosal | 2 | 2012 | 98 | 0.420 |
Why?
| | Injections, Intramuscular | 4 | 2017 | 147 | 0.410 |
Why?
| | Foscarnet | 6 | 2008 | 21 | 0.410 |
Why?
| | Immunophenotyping | 6 | 2019 | 320 | 0.400 |
Why?
| | Transplant Recipients | 3 | 2024 | 180 | 0.390 |
Why?
| | Gene Expression Profiling | 3 | 2019 | 1769 | 0.390 |
Why?
| | Antigen-Presenting Cells | 4 | 2022 | 159 | 0.390 |
Why?
| | B-Lymphocytes, Regulatory | 1 | 2013 | 3 | 0.390 |
Why?
| | CD4 Antigens | 2 | 2011 | 137 | 0.380 |
Why?
| | Abatacept | 3 | 2026 | 56 | 0.380 |
Why?
| | Influenza A Virus, H3N2 Subtype | 4 | 2020 | 50 | 0.370 |
Why?
| | Reverse Transcriptase Inhibitors | 3 | 2020 | 87 | 0.370 |
Why?
| | Staphylococcus aureus | 1 | 2017 | 455 | 0.370 |
Why?
| | Immune Tolerance | 2 | 2013 | 384 | 0.370 |
Why?
| | Alphapapillomavirus | 1 | 2012 | 35 | 0.370 |
Why?
| | Dendritic Cells | 2 | 2026 | 499 | 0.360 |
Why?
| | Vaccines, Conjugate | 2 | 2022 | 59 | 0.360 |
Why?
| | Cell Proliferation | 6 | 2020 | 2499 | 0.360 |
Why?
| | Hepatitis A | 1 | 2012 | 25 | 0.360 |
Why?
| | Candida | 3 | 2010 | 45 | 0.360 |
Why?
| | Placebos | 5 | 2017 | 193 | 0.350 |
Why?
| | Cohort Studies | 11 | 2023 | 5992 | 0.350 |
Why?
| | Polysaccharides | 2 | 2022 | 86 | 0.350 |
Why?
| | Skin | 1 | 2017 | 766 | 0.350 |
Why?
| | CD28 Antigens | 3 | 2009 | 59 | 0.350 |
Why?
| | Contraceptive Agents | 1 | 2012 | 65 | 0.340 |
Why?
| | Metapneumovirus | 1 | 2011 | 15 | 0.340 |
Why?
| | Transplantation | 1 | 2011 | 33 | 0.340 |
Why?
| | Herpesvirus 2, Human | 2 | 2012 | 27 | 0.340 |
Why?
| | Lymphocyte Count | 4 | 2019 | 165 | 0.340 |
Why?
| | Lymphoproliferative Disorders | 1 | 2011 | 57 | 0.340 |
Why?
| | Benzoxazines | 4 | 2026 | 31 | 0.340 |
Why?
| | T-Lymphocytes, Helper-Inducer | 7 | 1994 | 132 | 0.330 |
Why?
| | Blood | 2 | 2009 | 107 | 0.330 |
Why?
| | Immunogenicity, Vaccine | 5 | 2026 | 36 | 0.330 |
Why?
| | Nucleosides | 1 | 2010 | 25 | 0.330 |
Why?
| | Drug Therapy, Combination | 6 | 2019 | 1046 | 0.320 |
Why?
| | Retrospective Studies | 21 | 2024 | 17269 | 0.320 |
Why?
| | Pregnancy Outcome | 7 | 2021 | 497 | 0.320 |
Why?
| | Immunoglobulin A | 4 | 2017 | 214 | 0.310 |
Why?
| | Programmed Cell Death 1 Receptor | 3 | 2020 | 264 | 0.310 |
Why?
| | Cytosine | 3 | 2008 | 49 | 0.310 |
Why?
| | Streptococcus pneumoniae | 2 | 2022 | 180 | 0.310 |
Why?
| | Glycoproteins | 2 | 2023 | 353 | 0.310 |
Why?
| | Adaptive Immunity | 2 | 2017 | 169 | 0.310 |
Why?
| | Nucleotides | 1 | 2010 | 130 | 0.310 |
Why?
| | Antidepressive Agents | 3 | 2021 | 250 | 0.300 |
Why?
| | Refrigeration | 1 | 2009 | 12 | 0.300 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 8 | 2021 | 839 | 0.300 |
Why?
| | Membrane Glycoproteins | 4 | 2001 | 496 | 0.300 |
Why?
| | Immunity, Humoral | 2 | 2021 | 120 | 0.300 |
Why?
| | Follow-Up Studies | 16 | 2024 | 5426 | 0.300 |
Why?
| | Organophosphonates | 3 | 2008 | 97 | 0.300 |
Why?
| | Astrocytes | 1 | 2011 | 230 | 0.290 |
Why?
| | Prospective Studies | 15 | 2026 | 8039 | 0.290 |
Why?
| | Freezing | 1 | 2009 | 86 | 0.290 |
Why?
| | Coculture Techniques | 2 | 2025 | 246 | 0.290 |
Why?
| | Cytomegalovirus Retinitis | 2 | 2013 | 22 | 0.290 |
Why?
| | Tetanus | 2 | 2009 | 26 | 0.280 |
Why?
| | Cyclopropanes | 4 | 2026 | 84 | 0.280 |
Why?
| | Alkynes | 4 | 2026 | 66 | 0.280 |
Why?
| | Fetal Blood | 3 | 2026 | 325 | 0.280 |
Why?
| | Lopinavir | 3 | 2023 | 30 | 0.280 |
Why?
| | Interleukin-10 | 3 | 2022 | 313 | 0.280 |
Why?
| | Biomarkers | 8 | 2026 | 4283 | 0.270 |
Why?
| | Time Factors | 18 | 2017 | 7171 | 0.270 |
Why?
| | Herpesvirus 7, Human | 2 | 2005 | 6 | 0.270 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2008 | 100 | 0.270 |
Why?
| | Herpesvirus 6, Human | 2 | 2005 | 14 | 0.270 |
Why?
| | Glioblastoma | 1 | 2011 | 353 | 0.260 |
Why?
| | Longitudinal Studies | 8 | 2019 | 2950 | 0.260 |
Why?
| | Norgestrel | 1 | 2007 | 2 | 0.260 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2017 | 975 | 0.260 |
Why?
| | Interleukins | 2 | 2008 | 249 | 0.260 |
Why?
| | Specimen Handling | 1 | 2009 | 189 | 0.260 |
Why?
| | Apoptosis | 6 | 2011 | 2411 | 0.260 |
Why?
| | Incidence | 9 | 2023 | 2915 | 0.240 |
Why?
| | Nucleic Acid Hybridization | 2 | 2006 | 186 | 0.240 |
Why?
| | Antigens, CD | 5 | 2017 | 557 | 0.240 |
Why?
| | Lung Transplantation | 4 | 2002 | 330 | 0.230 |
Why?
| | Acetates | 2 | 2023 | 81 | 0.230 |
Why?
| | Coinfection | 2 | 2019 | 144 | 0.230 |
Why?
| | Lymphokines | 5 | 1994 | 128 | 0.230 |
Why?
| | Fibroblasts | 4 | 2025 | 1023 | 0.220 |
Why?
| | Bone Marrow Transplantation | 2 | 2005 | 297 | 0.220 |
Why?
| | Ritonavir | 2 | 2016 | 75 | 0.220 |
Why?
| | A549 Cells | 1 | 2025 | 75 | 0.220 |
Why?
| | Dexamethasone | 1 | 2007 | 366 | 0.220 |
Why?
| | Cell Survival | 5 | 2010 | 1094 | 0.220 |
Why?
| | Receptors, OX40 | 8 | 2001 | 15 | 0.220 |
Why?
| | Roseolovirus Infections | 1 | 2004 | 8 | 0.210 |
Why?
| | Paramyxoviridae | 1 | 2004 | 2 | 0.210 |
Why?
| | Measles Vaccine | 1 | 2024 | 19 | 0.210 |
Why?
| | Virus Replication | 5 | 2017 | 527 | 0.210 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2026 | 138 | 0.210 |
Why?
| | Quinazolines | 2 | 2023 | 266 | 0.210 |
Why?
| | BCG Vaccine | 2 | 2023 | 27 | 0.210 |
Why?
| | Ganciclovir | 4 | 2008 | 53 | 0.200 |
Why?
| | RNA, Messenger | 10 | 2011 | 2820 | 0.200 |
Why?
| | Autoimmune Diseases | 3 | 2014 | 469 | 0.200 |
Why?
| | Forkhead Transcription Factors | 3 | 2011 | 207 | 0.200 |
Why?
| | Milk, Human | 2 | 2023 | 174 | 0.200 |
Why?
| | Immunity | 2 | 2020 | 140 | 0.200 |
Why?
| | Brazil | 2 | 2021 | 183 | 0.200 |
Why?
| | Cholecalciferol | 1 | 2024 | 61 | 0.200 |
Why?
| | Estradiol | 1 | 2007 | 507 | 0.200 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 2 | 2017 | 261 | 0.200 |
Why?
| | Myelin Basic Protein | 4 | 1998 | 44 | 0.200 |
Why?
| | Orthomyxoviridae Infections | 1 | 2004 | 72 | 0.200 |
Why?
| | Down-Regulation | 1 | 2025 | 616 | 0.200 |
Why?
| | Maternal-Fetal Exchange | 2 | 2016 | 170 | 0.190 |
Why?
| | Acquired Immunodeficiency Syndrome | 2 | 2023 | 237 | 0.190 |
Why?
| | Kaposi Varicelliform Eruption | 3 | 2011 | 21 | 0.190 |
Why?
| | Papillomavirus Infections | 2 | 2018 | 343 | 0.190 |
Why?
| | Abnormalities, Drug-Induced | 1 | 2023 | 38 | 0.190 |
Why?
| | Long-Term Care | 1 | 2024 | 117 | 0.190 |
Why?
| | Antirheumatic Agents | 1 | 2026 | 308 | 0.190 |
Why?
| | Adenoviridae Infections | 1 | 2023 | 20 | 0.190 |
Why?
| | Heart Transplantation | 10 | 2001 | 676 | 0.190 |
Why?
| | Isoxazoles | 2 | 2013 | 55 | 0.180 |
Why?
| | Zidovudine | 2 | 2015 | 77 | 0.180 |
Why?
| | Diabetes Mellitus, Type 1 | 4 | 2013 | 3917 | 0.180 |
Why?
| | Lamivudine | 2 | 2015 | 65 | 0.180 |
Why?
| | Herpes Genitalis | 2 | 2012 | 17 | 0.180 |
Why?
| | HIV Integrase Inhibitors | 1 | 2023 | 79 | 0.180 |
Why?
| | Liver Failure, Acute | 1 | 2023 | 68 | 0.180 |
Why?
| | United States | 9 | 2024 | 16115 | 0.180 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 2 | 2013 | 97 | 0.180 |
Why?
| | Genes, Immediate-Early | 1 | 2002 | 26 | 0.180 |
Why?
| | Lymphocytosis | 1 | 2021 | 11 | 0.180 |
Why?
| | Risk Factors | 18 | 2024 | 10874 | 0.180 |
Why?
| | Genes, Viral | 1 | 2002 | 89 | 0.180 |
Why?
| | Central Nervous System Diseases | 1 | 2002 | 74 | 0.180 |
Why?
| | Antigens, Differentiation | 1 | 2001 | 76 | 0.170 |
Why?
| | Tuberculin Test | 1 | 2021 | 36 | 0.170 |
Why?
| | South Africa | 6 | 2020 | 266 | 0.170 |
Why?
| | Biliary Atresia | 1 | 2023 | 158 | 0.170 |
Why?
| | Interferon-gamma Release Tests | 1 | 2021 | 32 | 0.170 |
Why?
| | Cytotoxicity, Immunologic | 2 | 2002 | 226 | 0.170 |
Why?
| | Prenatal Exposure Delayed Effects | 2 | 2026 | 651 | 0.170 |
Why?
| | Maternal Exposure | 1 | 2023 | 188 | 0.170 |
Why?
| | Cells, Cultured | 11 | 2010 | 4127 | 0.170 |
Why?
| | Phenotype | 7 | 2009 | 3157 | 0.170 |
Why?
| | Organ Transplantation | 1 | 2024 | 251 | 0.170 |
Why?
| | Treatment Outcome | 17 | 2026 | 11831 | 0.170 |
Why?
| | Atazanavir Sulfate | 2 | 2023 | 42 | 0.170 |
Why?
| | Medication Therapy Management | 1 | 2021 | 72 | 0.170 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2021 | 76 | 0.170 |
Why?
| | Immunoglobulins | 2 | 2017 | 162 | 0.160 |
Why?
| | Evolution, Molecular | 1 | 2005 | 518 | 0.160 |
Why?
| | Receptors, Immunologic | 2 | 2000 | 206 | 0.160 |
Why?
| | Virus Activation | 3 | 2013 | 95 | 0.160 |
Why?
| | North America | 2 | 2023 | 312 | 0.160 |
Why?
| | Sensitivity and Specificity | 5 | 2009 | 2002 | 0.160 |
Why?
| | HIV Seronegativity | 1 | 2020 | 29 | 0.160 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2002 | 203 | 0.160 |
Why?
| | Virus Cultivation | 3 | 2005 | 31 | 0.160 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2022 | 565 | 0.150 |
Why?
| | Dietary Supplements | 1 | 2024 | 580 | 0.150 |
Why?
| | Heart-Assist Devices | 8 | 2000 | 569 | 0.150 |
Why?
| | T-Cell Antigen Receptor Specificity | 1 | 2019 | 45 | 0.150 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2019 | 82 | 0.150 |
Why?
| | Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 2 | 2017 | 13 | 0.150 |
Why?
| | Eicosanoids | 1 | 2019 | 58 | 0.150 |
Why?
| | Survival Analysis | 6 | 2018 | 1374 | 0.150 |
Why?
| | Dose-Response Relationship, Immunologic | 2 | 2016 | 76 | 0.140 |
Why?
| | Cholera Toxin | 1 | 2018 | 29 | 0.140 |
Why?
| | Arthritis, Rheumatoid | 2 | 2026 | 1177 | 0.140 |
Why?
| | Hospitals | 1 | 2023 | 732 | 0.140 |
Why?
| | Postoperative Complications | 14 | 2001 | 2962 | 0.140 |
Why?
| | Saliva | 2 | 2010 | 247 | 0.140 |
Why?
| | Genotype | 6 | 2020 | 1853 | 0.130 |
Why?
| | Delayed-Action Preparations | 2 | 2016 | 187 | 0.130 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2018 | 79 | 0.130 |
Why?
| | Latin America | 1 | 2018 | 97 | 0.130 |
Why?
| | Cell Movement | 2 | 2001 | 961 | 0.130 |
Why?
| | Neurodevelopmental Disorders | 1 | 2021 | 226 | 0.130 |
Why?
| | CD4-CD8 Ratio | 2 | 2008 | 23 | 0.130 |
Why?
| | Lysosomal-Associated Membrane Protein 1 | 1 | 2017 | 12 | 0.130 |
Why?
| | Vaccination Coverage | 1 | 2018 | 102 | 0.130 |
Why?
| | Cell Line | 5 | 2009 | 2823 | 0.130 |
Why?
| | Injections, Intradermal | 1 | 2017 | 11 | 0.130 |
Why?
| | Coronary Artery Bypass | 4 | 2001 | 271 | 0.130 |
Why?
| | Injections, Subcutaneous | 2 | 2016 | 170 | 0.130 |
Why?
| | Paralysis | 1 | 2017 | 69 | 0.120 |
Why?
| | Nervous System Diseases | 1 | 2020 | 287 | 0.120 |
Why?
| | Arm | 1 | 2017 | 111 | 0.120 |
Why?
| | Seroconversion | 1 | 2017 | 48 | 0.120 |
Why?
| | Placenta | 2 | 2021 | 784 | 0.120 |
Why?
| | Africa | 1 | 2017 | 119 | 0.120 |
Why?
| | Kinetics | 3 | 2010 | 1605 | 0.120 |
Why?
| | Nelfinavir | 1 | 2016 | 8 | 0.120 |
Why?
| | Adoptive Transfer | 3 | 2002 | 199 | 0.120 |
Why?
| | Animals | 24 | 2011 | 38141 | 0.120 |
Why?
| | Clinical Trials as Topic | 2 | 2019 | 1058 | 0.120 |
Why?
| | Cross Reactions | 2 | 2014 | 130 | 0.120 |
Why?
| | Base Sequence | 6 | 2017 | 2180 | 0.120 |
Why?
| | Demography | 2 | 2018 | 287 | 0.110 |
Why?
| | Colorado | 2 | 2023 | 4572 | 0.110 |
Why?
| | Seizures | 1 | 2020 | 482 | 0.110 |
Why?
| | Comorbidity | 2 | 2019 | 1659 | 0.110 |
Why?
| | Liver Transplantation | 1 | 2023 | 831 | 0.110 |
Why?
| | Aging | 3 | 2017 | 1940 | 0.110 |
Why?
| | Nevirapine | 1 | 2015 | 18 | 0.110 |
Why?
| | RNA | 1 | 2022 | 929 | 0.110 |
Why?
| | Contraceptives, Oral, Synthetic | 1 | 2015 | 1 | 0.110 |
Why?
| | Nasopharynx | 1 | 2015 | 73 | 0.110 |
Why?
| | Nasal Lavage Fluid | 2 | 2005 | 15 | 0.110 |
Why?
| | Immunoenzyme Techniques | 2 | 2006 | 199 | 0.110 |
Why?
| | Infant, Newborn, Diseases | 1 | 2016 | 115 | 0.110 |
Why?
| | Virus Latency | 2 | 2013 | 90 | 0.110 |
Why?
| | Transcription, Genetic | 1 | 2021 | 1468 | 0.110 |
Why?
| | Skin Diseases | 1 | 2016 | 152 | 0.100 |
Why?
| | Neutropenia | 1 | 2015 | 155 | 0.100 |
Why?
| | Seroepidemiologic Studies | 2 | 2024 | 171 | 0.100 |
Why?
| | Multivariate Analysis | 5 | 2017 | 1544 | 0.100 |
Why?
| | Computational Biology | 1 | 2019 | 687 | 0.100 |
Why?
| | Pandemics | 2 | 2021 | 1706 | 0.100 |
Why?
| | Graft Rejection | 5 | 2001 | 519 | 0.100 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 1 | 1994 | 104 | 0.100 |
Why?
| | Physical Fitness | 1 | 2015 | 207 | 0.100 |
Why?
| | Herpesvirus 8, Human | 2 | 2005 | 67 | 0.100 |
Why?
| | Progesterone | 2 | 2015 | 209 | 0.100 |
Why?
| | Drug Resistance, Multiple, Viral | 1 | 2013 | 10 | 0.100 |
Why?
| | Anemia | 1 | 2015 | 190 | 0.100 |
Why?
| | Feces | 1 | 2017 | 514 | 0.100 |
Why?
| | Thrombocytopenia | 1 | 2015 | 203 | 0.100 |
Why?
| | Leukocyte Common Antigens | 2 | 2009 | 87 | 0.100 |
Why?
| | Anesthesiology | 1 | 2016 | 178 | 0.090 |
Why?
| | Polyomavirus Infections | 1 | 2013 | 30 | 0.090 |
Why?
| | Epitopes | 2 | 2009 | 480 | 0.090 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2014 | 175 | 0.090 |
Why?
| | Tumor Virus Infections | 1 | 2013 | 51 | 0.090 |
Why?
| | Mothers | 1 | 2019 | 767 | 0.090 |
Why?
| | OX40 Ligand | 4 | 2001 | 10 | 0.090 |
Why?
| | Transcriptome | 1 | 2019 | 1038 | 0.090 |
Why?
| | Proctitis | 1 | 2012 | 6 | 0.090 |
Why?
| | Oxadiazoles | 1 | 2012 | 37 | 0.090 |
Why?
| | HIV Seropositivity | 1 | 2013 | 119 | 0.090 |
Why?
| | Oxidative Stress | 1 | 2019 | 1350 | 0.090 |
Why?
| | Rats, Inbred Lew | 4 | 1998 | 104 | 0.090 |
Why?
| | Aprotinin | 3 | 1997 | 9 | 0.090 |
Why?
| | Interferon Regulatory Factor-2 | 1 | 2011 | 3 | 0.090 |
Why?
| | DNA Primase | 1 | 2012 | 47 | 0.090 |
Why?
| | Mycophenolic Acid | 1 | 2012 | 120 | 0.090 |
Why?
| | Communicable Diseases | 1 | 2014 | 166 | 0.090 |
Why?
| | Fluorescent Antibody Technique, Direct | 1 | 2011 | 9 | 0.090 |
Why?
| | Depression | 1 | 2021 | 1573 | 0.090 |
Why?
| | Viral Plaque Assay | 3 | 2006 | 29 | 0.090 |
Why?
| | L-Selectin | 2 | 2009 | 27 | 0.090 |
Why?
| | Receptors, Interleukin-2 | 2 | 1990 | 64 | 0.080 |
Why?
| | Histocompatibility Testing | 3 | 2001 | 123 | 0.080 |
Why?
| | CD8 Antigens | 1 | 2011 | 70 | 0.080 |
Why?
| | Guanine | 3 | 2006 | 85 | 0.080 |
Why?
| | Encephalitis, Viral | 2 | 2020 | 45 | 0.080 |
Why?
| | Ribavirin | 1 | 2011 | 81 | 0.080 |
Why?
| | Immunization Schedule | 3 | 2020 | 186 | 0.080 |
Why?
| | DNA Helicases | 1 | 2012 | 141 | 0.080 |
Why?
| | Fluorescent Antibody Technique | 2 | 2016 | 364 | 0.080 |
Why?
| | Motor Activity | 1 | 2015 | 723 | 0.080 |
Why?
| | Parturition | 1 | 2011 | 68 | 0.080 |
Why?
| | Logistic Models | 5 | 2010 | 2130 | 0.080 |
Why?
| | Herpesvirus Vaccines | 1 | 2010 | 4 | 0.080 |
Why?
| | Predictive Value of Tests | 3 | 2005 | 2129 | 0.080 |
Why?
| | Length of Stay | 3 | 2014 | 1348 | 0.080 |
Why?
| | Menstrual Cycle | 1 | 2011 | 140 | 0.080 |
Why?
| | Algorithms | 3 | 2021 | 1855 | 0.080 |
Why?
| | Immune System | 2 | 2008 | 178 | 0.080 |
Why?
| | Granzymes | 1 | 2009 | 49 | 0.080 |
Why?
| | Herpes Simplex Virus Vaccines | 1 | 2009 | 4 | 0.080 |
Why?
| | Pokeweed Mitogens | 1 | 2009 | 6 | 0.080 |
Why?
| | Human Experimentation | 1 | 2009 | 11 | 0.070 |
Why?
| | Neuralgia, Postherpetic | 1 | 2009 | 40 | 0.070 |
Why?
| | Pilot Projects | 2 | 2026 | 1896 | 0.070 |
Why?
| | Immunologic Factors | 1 | 2011 | 260 | 0.070 |
Why?
| | Drug Stability | 1 | 2009 | 169 | 0.070 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2009 | 185 | 0.070 |
Why?
| | Plasma | 2 | 2018 | 225 | 0.070 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2014 | 1212 | 0.070 |
Why?
| | Gene Rearrangement, T-Lymphocyte | 1 | 2008 | 16 | 0.070 |
Why?
| | Cost of Illness | 1 | 2011 | 324 | 0.070 |
Why?
| | Nasal Mucosa | 1 | 2009 | 112 | 0.070 |
Why?
| | Inflammation Mediators | 1 | 2011 | 505 | 0.070 |
Why?
| | Mice | 13 | 2011 | 18338 | 0.070 |
Why?
| | Enzyme Inhibitors | 1 | 2012 | 821 | 0.070 |
Why?
| | Botswana | 2 | 2019 | 11 | 0.070 |
Why?
| | Betaherpesvirinae | 1 | 2008 | 1 | 0.070 |
Why?
| | Genetic Variation | 2 | 2011 | 988 | 0.070 |
Why?
| | Infant Mortality | 2 | 2019 | 128 | 0.070 |
Why?
| | Exodeoxyribonucleases | 1 | 2008 | 23 | 0.070 |
Why?
| | Administration, Intranasal | 1 | 2008 | 94 | 0.070 |
Why?
| | Cyclosporine | 2 | 2001 | 256 | 0.070 |
Why?
| | Interleukin-15 | 1 | 2008 | 96 | 0.070 |
Why?
| | Interleukin-12 | 1 | 2008 | 117 | 0.070 |
Why?
| | Rats | 5 | 1998 | 5581 | 0.070 |
Why?
| | Trypan Blue | 1 | 2007 | 5 | 0.070 |
Why?
| | Didanosine | 1 | 2007 | 13 | 0.070 |
Why?
| | Sarcoma | 1 | 2010 | 204 | 0.070 |
Why?
| | Thymus Gland | 1 | 2008 | 311 | 0.070 |
Why?
| | Gene Expression | 3 | 2006 | 1478 | 0.060 |
Why?
| | In Vitro Techniques | 3 | 2006 | 1047 | 0.060 |
Why?
| | Data Interpretation, Statistical | 1 | 2009 | 369 | 0.060 |
Why?
| | Quality Control | 1 | 2007 | 164 | 0.060 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2010 | 296 | 0.060 |
Why?
| | Cerebrospinal Fluid | 2 | 2004 | 88 | 0.060 |
Why?
| | Pneumonia | 1 | 2013 | 632 | 0.060 |
Why?
| | Inhibitory Concentration 50 | 1 | 2006 | 90 | 0.060 |
Why?
| | Vero Cells | 1 | 2006 | 84 | 0.060 |
Why?
| | Transfection | 3 | 2002 | 925 | 0.060 |
Why?
| | Drug Interactions | 2 | 2020 | 404 | 0.060 |
Why?
| | Multicenter Studies as Topic | 2 | 2006 | 411 | 0.060 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2011 | 1755 | 0.060 |
Why?
| | Veterans | 1 | 2018 | 1626 | 0.060 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2012 | 994 | 0.060 |
Why?
| | Deoxycytidine | 1 | 2007 | 222 | 0.060 |
Why?
| | Protein Structure, Tertiary | 1 | 2008 | 850 | 0.060 |
Why?
| | Opportunistic Infections | 2 | 2014 | 47 | 0.060 |
Why?
| | Hemadsorption | 1 | 2005 | 1 | 0.060 |
Why?
| | Cytopathogenic Effect, Viral | 1 | 2005 | 16 | 0.060 |
Why?
| | Tumor Necrosis Factors | 3 | 2001 | 10 | 0.060 |
Why?
| | Hemostatics | 2 | 1997 | 63 | 0.060 |
Why?
| | Disease Models, Animal | 2 | 2011 | 4559 | 0.060 |
Why?
| | Signal Transduction | 2 | 2000 | 5202 | 0.060 |
Why?
| | Risk Assessment | 2 | 2014 | 3759 | 0.060 |
Why?
| | Evaluation Studies as Topic | 1 | 2005 | 164 | 0.060 |
Why?
| | Gene Products, pol | 1 | 2005 | 6 | 0.060 |
Why?
| | Annexin A5 | 1 | 2004 | 22 | 0.050 |
Why?
| | Clinical Trials, Phase II as Topic | 2 | 2017 | 76 | 0.050 |
Why?
| | Cysteine Proteinase Inhibitors | 1 | 2004 | 49 | 0.050 |
Why?
| | Antigens | 2 | 2008 | 349 | 0.050 |
Why?
| | Meningitis, Viral | 1 | 2004 | 20 | 0.050 |
Why?
| | Pharmacogenetics | 1 | 2026 | 173 | 0.050 |
Why?
| | Parainfluenza Virus 2, Human | 1 | 2004 | 3 | 0.050 |
Why?
| | Parainfluenza Virus 1, Human | 1 | 2004 | 3 | 0.050 |
Why?
| | Parainfluenza Virus 3, Human | 1 | 2004 | 5 | 0.050 |
Why?
| | Sarcoma, Kaposi | 2 | 2003 | 83 | 0.050 |
Why?
| | Measles virus | 1 | 2024 | 21 | 0.050 |
Why?
| | Disease Transmission, Infectious | 1 | 2005 | 69 | 0.050 |
Why?
| | Transplantation, Homologous | 2 | 2002 | 420 | 0.050 |
Why?
| | Adenoviruses, Human | 1 | 2004 | 26 | 0.050 |
Why?
| | Emtricitabine | 2 | 2021 | 209 | 0.050 |
Why?
| | Cell Culture Techniques | 1 | 2006 | 373 | 0.050 |
Why?
| | Fatal Outcome | 1 | 2005 | 306 | 0.050 |
Why?
| | Immunotherapy, Adoptive | 2 | 2001 | 342 | 0.050 |
Why?
| | Chlamydophila Infections | 1 | 2003 | 5 | 0.050 |
Why?
| | Chlamydophila pneumoniae | 1 | 2003 | 12 | 0.050 |
Why?
| | Measles | 1 | 2024 | 46 | 0.050 |
Why?
| | HLA-DR Antigens | 3 | 2001 | 220 | 0.050 |
Why?
| | Rilpivirine | 1 | 2023 | 10 | 0.050 |
Why?
| | Bronchiolitis Obliterans | 2 | 2001 | 61 | 0.050 |
Why?
| | Arteriosclerosis | 1 | 2003 | 83 | 0.050 |
Why?
| | Survival Rate | 8 | 2001 | 2093 | 0.050 |
Why?
| | Portoenterostomy, Hepatic | 1 | 2023 | 43 | 0.050 |
Why?
| | Darunavir | 1 | 2023 | 20 | 0.050 |
Why?
| | Herpes Labialis | 1 | 2003 | 8 | 0.050 |
Why?
| | Cell Line, Tumor | 1 | 2011 | 3537 | 0.050 |
Why?
| | Hospital Mortality | 4 | 2001 | 1044 | 0.050 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2010 | 686 | 0.050 |
Why?
| | DNA Primers | 3 | 2009 | 507 | 0.050 |
Why?
| | Respirovirus | 1 | 2002 | 6 | 0.050 |
Why?
| | Pregnancy Trimester, First | 1 | 2023 | 138 | 0.050 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 2 | 1994 | 333 | 0.050 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2005 | 636 | 0.050 |
Why?
| | Risk | 1 | 2005 | 917 | 0.040 |
Why?
| | Parapsychology | 1 | 2001 | 1 | 0.040 |
Why?
| | Adenoviridae | 1 | 2023 | 199 | 0.040 |
Why?
| | Electromagnetic Fields | 1 | 2001 | 37 | 0.040 |
Why?
| | Zimbabwe | 2 | 2017 | 76 | 0.040 |
Why?
| | B7-1 Antigen | 2 | 1998 | 55 | 0.040 |
Why?
| | Ovalbumin | 1 | 2001 | 194 | 0.040 |
Why?
| | Molecular Sequence Data | 4 | 1994 | 2910 | 0.040 |
Why?
| | Microbial Sensitivity Tests | 1 | 2003 | 378 | 0.040 |
Why?
| | Cobicistat | 1 | 2021 | 5 | 0.040 |
Why?
| | Receptors, CXCR5 | 1 | 2021 | 27 | 0.040 |
Why?
| | Antibody Affinity | 1 | 2021 | 60 | 0.040 |
Why?
| | CTLA-4 Antigen | 1 | 2001 | 105 | 0.040 |
Why?
| | Rituximab | 2 | 2013 | 211 | 0.040 |
Why?
| | Photography | 1 | 2001 | 119 | 0.040 |
Why?
| | Liver Diseases | 1 | 2024 | 304 | 0.040 |
Why?
| | Vaccines, Subunit | 1 | 2021 | 53 | 0.040 |
Why?
| | Prostheses and Implants | 3 | 1996 | 142 | 0.040 |
Why?
| | Gene Expression Regulation | 1 | 1990 | 2594 | 0.040 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2002 | 133 | 0.040 |
Why?
| | Arylamine N-Acetyltransferase | 1 | 2020 | 8 | 0.040 |
Why?
| | Cytochrome P-450 CYP2B6 | 1 | 2020 | 9 | 0.040 |
Why?
| | Lymphoma | 1 | 2002 | 234 | 0.040 |
Why?
| | Equivalence Trials as Topic | 1 | 2020 | 36 | 0.040 |
Why?
| | Pre-Eclampsia | 1 | 2023 | 206 | 0.040 |
Why?
| | Analysis of Variance | 2 | 2016 | 1304 | 0.040 |
Why?
| | Models, Statistical | 1 | 2005 | 679 | 0.040 |
Why?
| | Sentinel Lymph Node Biopsy | 1 | 2001 | 117 | 0.040 |
Why?
| | Metabolic Clearance Rate | 1 | 2020 | 115 | 0.040 |
Why?
| | Living Donors | 1 | 2023 | 282 | 0.040 |
Why?
| | Surface Properties | 1 | 2001 | 398 | 0.040 |
Why?
| | DNA | 2 | 2006 | 1451 | 0.040 |
Why?
| | Glioma | 1 | 2005 | 429 | 0.040 |
Why?
| | Spinal Cord | 2 | 1994 | 384 | 0.040 |
Why?
| | Central Nervous System Neoplasms | 1 | 2002 | 177 | 0.040 |
Why?
| | Trans-Activators | 1 | 2002 | 397 | 0.040 |
Why?
| | Lymphatic Metastasis | 1 | 2001 | 335 | 0.040 |
Why?
| | Heart Failure | 3 | 1999 | 2329 | 0.040 |
Why?
| | Alanine | 1 | 2021 | 170 | 0.040 |
Why?
| | Confusion | 1 | 2020 | 30 | 0.040 |
Why?
| | Cancer Vaccines | 1 | 2001 | 161 | 0.040 |
Why?
| | Hemodynamics | 3 | 2001 | 1116 | 0.040 |
Why?
| | Interleukin-3 | 3 | 1994 | 23 | 0.040 |
Why?
| | Coronary Disease | 2 | 2001 | 381 | 0.040 |
Why?
| | Antibodies | 1 | 2001 | 398 | 0.040 |
Why?
| | Liver Function Tests | 1 | 2019 | 105 | 0.040 |
Why?
| | Candidiasis | 1 | 1999 | 64 | 0.040 |
Why?
| | Triiodothyronine | 1 | 1999 | 54 | 0.040 |
Why?
| | Recombinant Fusion Proteins | 2 | 1999 | 667 | 0.040 |
Why?
| | Prognosis | 3 | 2024 | 4323 | 0.040 |
Why?
| | Infant, Very Low Birth Weight | 1 | 2019 | 75 | 0.040 |
Why?
| | Hemagglutination | 1 | 2018 | 7 | 0.040 |
Why?
| | California | 2 | 2015 | 483 | 0.040 |
Why?
| | Macrophage-1 Antigen | 1 | 1999 | 26 | 0.040 |
Why?
| | Hypoplastic Left Heart Syndrome | 1 | 2000 | 117 | 0.040 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2011 | 2146 | 0.040 |
Why?
| | Mice, Inbred BALB C | 1 | 2001 | 1261 | 0.040 |
Why?
| | Arginine Vasopressin | 1 | 1998 | 44 | 0.040 |
Why?
| | Tenofovir | 1 | 2021 | 300 | 0.040 |
Why?
| | Cross-Sectional Studies | 3 | 2024 | 5891 | 0.040 |
Why?
| | Brain Diseases | 1 | 2020 | 153 | 0.040 |
Why?
| | Adenine | 1 | 2021 | 338 | 0.030 |
Why?
| | Neoplasms | 3 | 2001 | 2897 | 0.030 |
Why?
| | HLA-B Antigens | 1 | 1998 | 58 | 0.030 |
Why?
| | Haptoglobins | 1 | 2018 | 71 | 0.030 |
Why?
| | Chronic Disease | 1 | 2024 | 1816 | 0.030 |
Why?
| | Delivery, Obstetric | 1 | 2019 | 161 | 0.030 |
Why?
| | Antibody Specificity | 1 | 1998 | 178 | 0.030 |
Why?
| | Vasoconstrictor Agents | 1 | 1998 | 150 | 0.030 |
Why?
| | Immunization | 1 | 2020 | 375 | 0.030 |
Why?
| | Protein Precursors | 1 | 2018 | 136 | 0.030 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2017 | 50 | 0.030 |
Why?
| | Inositol Phosphates | 1 | 2017 | 21 | 0.030 |
Why?
| | Sterols | 1 | 2017 | 20 | 0.030 |
Why?
| | Shock | 1 | 1998 | 109 | 0.030 |
Why?
| | Autogenic Training | 1 | 1997 | 1 | 0.030 |
Why?
| | Proviruses | 1 | 2017 | 16 | 0.030 |
Why?
| | Radioactive Fallout | 1 | 1997 | 1 | 0.030 |
Why?
| | Leukemia, Radiation-Induced | 1 | 1997 | 4 | 0.030 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2017 | 74 | 0.030 |
Why?
| | Radioactive Hazard Release | 1 | 1997 | 5 | 0.030 |
Why?
| | Sequence Analysis | 1 | 2017 | 35 | 0.030 |
Why?
| | Observational Studies as Topic | 1 | 2017 | 133 | 0.030 |
Why?
| | Power Plants | 1 | 1997 | 9 | 0.030 |
Why?
| | Relaxation Therapy | 1 | 1997 | 19 | 0.030 |
Why?
| | Zambia | 1 | 2017 | 58 | 0.030 |
Why?
| | Tanzania | 1 | 2017 | 72 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2005 | 3424 | 0.030 |
Why?
| | Encephalitis | 1 | 1998 | 142 | 0.030 |
Why?
| | Ligands | 1 | 1999 | 667 | 0.030 |
Why?
| | Heart Valves | 1 | 1997 | 44 | 0.030 |
Why?
| | Lung Injury | 1 | 2000 | 241 | 0.030 |
Why?
| | Aortic Valve Insufficiency | 1 | 1996 | 43 | 0.030 |
Why?
| | Body Weight | 1 | 2020 | 970 | 0.030 |
Why?
| | Erythema | 1 | 2016 | 28 | 0.030 |
Why?
| | Prevalence | 2 | 2018 | 2855 | 0.030 |
Why?
| | Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2016 | 29 | 0.030 |
Why?
| | Up-Regulation | 2 | 2001 | 848 | 0.030 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 1997 | 100 | 0.030 |
Why?
| | Fiber Optic Technology | 1 | 2016 | 23 | 0.030 |
Why?
| | Heart Arrest, Induced | 1 | 1995 | 26 | 0.030 |
Why?
| | Chi-Square Distribution | 2 | 2013 | 529 | 0.030 |
Why?
| | Thromboembolism | 1 | 1996 | 128 | 0.030 |
Why?
| | Vasodilation | 1 | 1998 | 521 | 0.030 |
Why?
| | Intestines | 1 | 2018 | 357 | 0.030 |
Why?
| | Reference Values | 2 | 2011 | 797 | 0.030 |
Why?
| | Interleukin-4 | 2 | 1998 | 208 | 0.030 |
Why?
| | Graft vs Host Disease | 1 | 1998 | 281 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2002 | 1487 | 0.030 |
Why?
| | Single-Blind Method | 1 | 2016 | 319 | 0.030 |
Why?
| | Ovulation | 1 | 2015 | 40 | 0.030 |
Why?
| | Blood Transfusion | 2 | 1995 | 408 | 0.030 |
Why?
| | Registries | 1 | 2024 | 2410 | 0.030 |
Why?
| | Antibodies, Monoclonal | 2 | 2001 | 1511 | 0.030 |
Why?
| | Hematologic Neoplasms | 1 | 1997 | 168 | 0.030 |
Why?
| | Cross Infection | 1 | 1997 | 264 | 0.030 |
Why?
| | Liver | 1 | 2023 | 1895 | 0.030 |
Why?
| | Rats, Inbred BUF | 1 | 1994 | 1 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2017 | 320 | 0.030 |
Why?
| | Hypothermia, Induced | 1 | 1995 | 95 | 0.030 |
Why?
| | Blood Loss, Surgical | 1 | 1995 | 112 | 0.030 |
Why?
| | HLA-A2 Antigen | 1 | 2014 | 36 | 0.030 |
Why?
| | Pulmonary Emphysema | 1 | 1996 | 277 | 0.030 |
Why?
| | Surgical Wound Infection | 1 | 1997 | 330 | 0.030 |
Why?
| | Aortic Coarctation | 1 | 1994 | 78 | 0.030 |
Why?
| | Polymorphism, Restriction Fragment Length | 2 | 2003 | 63 | 0.030 |
Why?
| | Colony-Stimulating Factors | 2 | 1990 | 37 | 0.020 |
Why?
| | Cross-Over Studies | 1 | 2016 | 607 | 0.020 |
Why?
| | Aortic Valve | 1 | 1996 | 364 | 0.020 |
Why?
| | Quality of Life | 4 | 2000 | 3195 | 0.020 |
Why?
| | Myocardial Infarction | 1 | 2001 | 1216 | 0.020 |
Why?
| | Growth Substances | 2 | 1990 | 138 | 0.020 |
Why?
| | BK Virus | 1 | 2013 | 18 | 0.020 |
Why?
| | JC Virus | 1 | 2013 | 23 | 0.020 |
Why?
| | Cause of Death | 3 | 2001 | 469 | 0.020 |
Why?
| | Intubation, Intratracheal | 1 | 2016 | 326 | 0.020 |
Why?
| | Herpesviridae | 1 | 2012 | 22 | 0.020 |
Why?
| | Mice, Inbred Strains | 2 | 1990 | 396 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 2 | 2011 | 2355 | 0.020 |
Why?
| | Drug Administration Schedule | 2 | 2007 | 782 | 0.020 |
Why?
| | Cardiac Surgical Procedures | 1 | 1998 | 613 | 0.020 |
Why?
| | Hypersensitivity, Delayed | 1 | 1992 | 29 | 0.020 |
Why?
| | Heart Diseases | 1 | 1995 | 342 | 0.020 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 1990 | 161 | 0.020 |
Why?
| | Brain Neoplasms | 1 | 2001 | 1329 | 0.020 |
Why?
| | Ventricular Function, Left | 1 | 1995 | 539 | 0.020 |
Why?
| | Spleen | 1 | 1994 | 511 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2014 | 974 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2001 | 1965 | 0.020 |
Why?
| | Histocompatibility Antigens | 1 | 1992 | 102 | 0.020 |
Why?
| | Sex Characteristics | 1 | 2017 | 779 | 0.020 |
Why?
| | Ambulatory Care | 1 | 1996 | 608 | 0.020 |
Why?
| | Metabolomics | 1 | 2017 | 729 | 0.020 |
Why?
| | Patient Selection | 1 | 1995 | 742 | 0.020 |
Why?
| | Computer Simulation | 1 | 2016 | 1026 | 0.020 |
Why?
| | Matched-Pair Analysis | 1 | 2011 | 37 | 0.020 |
Why?
| | Receptors, Interferon | 1 | 2011 | 60 | 0.020 |
Why?
| | Kidney Failure, Chronic | 1 | 1997 | 600 | 0.020 |
Why?
| | Age of Onset | 1 | 2012 | 554 | 0.020 |
Why?
| | Cattle | 2 | 1990 | 977 | 0.020 |
Why?
| | Administration, Oral | 1 | 2013 | 863 | 0.020 |
Why?
| | Radiotherapy | 2 | 2005 | 205 | 0.020 |
Why?
| | Stroke | 1 | 2000 | 1272 | 0.020 |
Why?
| | Polyribosomes | 1 | 1990 | 22 | 0.020 |
Why?
| | Cell Separation | 1 | 2011 | 304 | 0.020 |
Why?
| | Lung Neoplasms | 2 | 2001 | 2664 | 0.020 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 1990 | 156 | 0.020 |
Why?
| | Concanavalin A | 1 | 1990 | 72 | 0.020 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 1990 | 150 | 0.020 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 1990 | 93 | 0.020 |
Why?
| | Blotting, Northern | 1 | 1990 | 203 | 0.020 |
Why?
| | Papillomaviridae | 1 | 2010 | 116 | 0.020 |
Why?
| | Haplotypes | 1 | 2011 | 498 | 0.020 |
Why?
| | Genetic Association Studies | 1 | 2011 | 369 | 0.020 |
Why?
| | Infant, Premature | 1 | 2014 | 619 | 0.020 |
Why?
| | beta-Globins | 1 | 2009 | 8 | 0.020 |
Why?
| | Cell Division | 2 | 2002 | 753 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1585 | 0.020 |
Why?
| | Mice, Knockout | 2 | 2011 | 3125 | 0.020 |
Why?
| | Herpesvirus 1, Bovine | 1 | 1989 | 3 | 0.020 |
Why?
| | Anxiety | 1 | 1997 | 1127 | 0.020 |
Why?
| | Immunoglobulin E | 1 | 2010 | 315 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2011 | 751 | 0.020 |
Why?
| | Hematopoietic Stem Cells | 2 | 1990 | 419 | 0.020 |
Why?
| | Reference Standards | 1 | 2009 | 178 | 0.020 |
Why?
| | Ribosomes | 1 | 1990 | 196 | 0.020 |
Why?
| | Phylogeny | 1 | 2013 | 1028 | 0.020 |
Why?
| | Multiple Sclerosis | 1 | 1994 | 488 | 0.020 |
Why?
| | Linear Models | 1 | 2010 | 848 | 0.020 |
Why?
| | Infusions, Intravenous | 2 | 1999 | 427 | 0.020 |
Why?
| | Membrane Proteins | 1 | 1994 | 1164 | 0.020 |
Why?
| | Clinical Competence | 1 | 2016 | 1242 | 0.020 |
Why?
| | Time | 1 | 2007 | 86 | 0.020 |
Why?
| | Protein Biosynthesis | 1 | 1990 | 455 | 0.020 |
Why?
| | Drug Resistance, Multiple | 1 | 2006 | 25 | 0.020 |
Why?
| | Kidney Transplantation | 1 | 2013 | 711 | 0.020 |
Why?
| | Antineoplastic Agents | 2 | 2010 | 2207 | 0.020 |
Why?
| | Clinical Protocols | 1 | 2007 | 282 | 0.010 |
Why?
| | Templates, Genetic | 1 | 2005 | 63 | 0.010 |
Why?
| | Postoperative Care | 2 | 1999 | 286 | 0.010 |
Why?
| | Cell Differentiation | 4 | 2000 | 2045 | 0.010 |
Why?
| | Codon | 1 | 2005 | 93 | 0.010 |
Why?
| | Internship and Residency | 1 | 2016 | 1265 | 0.010 |
Why?
| | Interleukin-5 | 2 | 1998 | 39 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2009 | 1507 | 0.010 |
Why?
| | DNA Replication | 1 | 2006 | 252 | 0.010 |
Why?
| | Mice, Transgenic | 2 | 2000 | 2189 | 0.010 |
Why?
| | Age Distribution | 1 | 2005 | 403 | 0.010 |
Why?
| | Sex Distribution | 1 | 2005 | 387 | 0.010 |
Why?
| | Vaccines | 1 | 2009 | 388 | 0.010 |
Why?
| | Creatinine | 2 | 1997 | 513 | 0.010 |
Why?
| | Abdominal Neoplasms | 1 | 2003 | 47 | 0.010 |
Why?
| | Lung | 1 | 1996 | 4103 | 0.010 |
Why?
| | Endemic Diseases | 1 | 2003 | 33 | 0.010 |
Why?
| | Disease Progression | 1 | 2010 | 2862 | 0.010 |
Why?
| | Peptide Fragments | 2 | 1998 | 693 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2005 | 831 | 0.010 |
Why?
| | Bioelectric Energy Sources | 1 | 2001 | 4 | 0.010 |
Why?
| | Neuroblastoma | 1 | 2003 | 174 | 0.010 |
Why?
| | Fibrosarcoma | 1 | 2001 | 23 | 0.010 |
Why?
| | Galvanic Skin Response | 1 | 2001 | 26 | 0.010 |
Why?
| | Electricity | 1 | 2001 | 27 | 0.010 |
Why?
| | Electric Conductivity | 1 | 2001 | 85 | 0.010 |
Why?
| | Actuarial Analysis | 1 | 2001 | 16 | 0.010 |
Why?
| | Injections, Intravenous | 1 | 2001 | 199 | 0.010 |
Why?
| | Melanoma, Experimental | 1 | 2001 | 109 | 0.010 |
Why?
| | HLA-A Antigens | 1 | 2001 | 52 | 0.010 |
Why?
| | Fingers | 1 | 2001 | 108 | 0.010 |
Why?
| | Myocardial Revascularization | 1 | 2001 | 85 | 0.010 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2003 | 444 | 0.010 |
Why?
| | Statistics, Nonparametric | 1 | 2001 | 432 | 0.010 |
Why?
| | Immune Sera | 1 | 2000 | 77 | 0.010 |
Why?
| | Anticoagulants | 2 | 1996 | 750 | 0.010 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2001 | 153 | 0.010 |
Why?
| | Amino Acid Sequence | 2 | 1994 | 2137 | 0.010 |
Why?
| | Probability | 1 | 2001 | 310 | 0.010 |
Why?
| | Clone Cells | 1 | 2000 | 264 | 0.010 |
Why?
| | Mice, Inbred C57BL | 2 | 2001 | 5989 | 0.010 |
Why?
| | Emergency Treatment | 1 | 2001 | 124 | 0.010 |
Why?
| | Databases as Topic | 1 | 2000 | 71 | 0.010 |
Why?
| | New York | 1 | 2000 | 127 | 0.010 |
Why?
| | Carotid Artery Diseases | 1 | 2000 | 70 | 0.010 |
Why?
| | Students | 1 | 2005 | 658 | 0.010 |
Why?
| | Peripheral Vascular Diseases | 1 | 2000 | 107 | 0.010 |
Why?
| | Columbidae | 1 | 1998 | 31 | 0.010 |
Why?
| | Cytochrome c Group | 1 | 1998 | 42 | 0.010 |
Why?
| | Cardiotonic Agents | 1 | 1999 | 94 | 0.010 |
Why?
| | Lymph Nodes | 1 | 2001 | 502 | 0.010 |
Why?
| | Cardiac Output | 1 | 1999 | 179 | 0.010 |
Why?
| | Life Tables | 1 | 1998 | 21 | 0.010 |
Why?
| | Endocardium | 1 | 1998 | 32 | 0.010 |
Why?
| | Temperature | 1 | 2001 | 681 | 0.010 |
Why?
| | Aortic Diseases | 1 | 2000 | 127 | 0.010 |
Why?
| | Vascular Resistance | 1 | 1999 | 369 | 0.010 |
Why?
| | Calcinosis | 1 | 2000 | 235 | 0.010 |
Why?
| | Cell Death | 1 | 1999 | 383 | 0.010 |
Why?
| | Renal Insufficiency | 1 | 2000 | 172 | 0.010 |
Why?
| | Cardiopulmonary Bypass | 1 | 2000 | 217 | 0.010 |
Why?
| | Hypotension | 1 | 1998 | 127 | 0.010 |
Why?
| | Phosphorylation | 1 | 2002 | 1707 | 0.010 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 1998 | 229 | 0.010 |
Why?
| | Ukraine | 1 | 1997 | 36 | 0.010 |
Why?
| | Endocarditis, Bacterial | 1 | 1997 | 46 | 0.010 |
Why?
| | Odds Ratio | 1 | 2000 | 1082 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2001 | 2030 | 0.010 |
Why?
| | Models, Structural | 1 | 1996 | 41 | 0.010 |
Why?
| | Lung Volume Measurements | 1 | 1996 | 46 | 0.010 |
Why?
| | Radiometry | 1 | 1997 | 56 | 0.010 |
Why?
| | Histocompatibility Antigens Class II | 1 | 1998 | 365 | 0.010 |
Why?
| | Epidemiologic Methods | 1 | 1997 | 91 | 0.010 |
Why?
| | Ultrasonography, Doppler, Transcranial | 1 | 1996 | 48 | 0.010 |
Why?
| | Health Care Costs | 1 | 2000 | 427 | 0.010 |
Why?
| | Cardiac Output, Low | 1 | 1996 | 53 | 0.010 |
Why?
| | Equipment Failure | 1 | 1996 | 116 | 0.010 |
Why?
| | Urogenital Neoplasms | 1 | 1995 | 5 | 0.010 |
Why?
| | Vital Capacity | 1 | 1996 | 292 | 0.010 |
Why?
| | Europe | 1 | 1997 | 421 | 0.010 |
Why?
| | Pneumonia, Viral | 1 | 2001 | 389 | 0.010 |
Why?
| | Neoplasms, Second Primary | 1 | 1997 | 102 | 0.010 |
Why?
| | Forced Expiratory Volume | 1 | 1996 | 450 | 0.010 |
Why?
| | Models, Cardiovascular | 1 | 1996 | 197 | 0.010 |
Why?
| | Blood Urea Nitrogen | 1 | 1995 | 53 | 0.010 |
Why?
| | Heart Valve Prosthesis | 1 | 1997 | 132 | 0.010 |
Why?
| | Aortic Aneurysm | 1 | 1995 | 70 | 0.010 |
Why?
| | Acute Disease | 1 | 1998 | 1040 | 0.010 |
Why?
| | Heart Rate | 1 | 1999 | 859 | 0.010 |
Why?
| | Child Development | 1 | 2000 | 484 | 0.010 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 1998 | 673 | 0.010 |
Why?
| | Biopsy | 1 | 1998 | 1081 | 0.010 |
Why?
| | Equipment Design | 1 | 1996 | 532 | 0.010 |
Why?
| | Hodgkin Disease | 1 | 1997 | 171 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 1998 | 1332 | 0.010 |
Why?
| | Waiting Lists | 1 | 1996 | 266 | 0.010 |
Why?
| | Heart Septal Defects, Ventricular | 1 | 1994 | 47 | 0.010 |
Why?
| | Interviews as Topic | 1 | 1997 | 909 | 0.010 |
Why?
| | Reoperation | 1 | 1997 | 631 | 0.010 |
Why?
| | Exercise Test | 1 | 1996 | 628 | 0.010 |
Why?
| | Cell Adhesion | 1 | 1994 | 452 | 0.010 |
Why?
| | Myocardium | 1 | 1998 | 932 | 0.010 |
Why?
| | Smoking | 1 | 2000 | 1468 | 0.010 |
Why?
| | Thyroid Neoplasms | 1 | 1997 | 349 | 0.010 |
Why?
| | Ventricular Function, Right | 1 | 1995 | 296 | 0.010 |
Why?
| | Patient Compliance | 1 | 1997 | 587 | 0.010 |
Why?
| | Central Nervous System | 1 | 1994 | 282 | 0.010 |
Why?
| | Feasibility Studies | 1 | 1996 | 1119 | 0.010 |
Why?
| | Blood Pressure | 1 | 1998 | 1782 | 0.010 |
Why?
| | Diabetes Mellitus | 1 | 2000 | 1076 | 0.010 |
Why?
| | Head and Neck Neoplasms | 1 | 1995 | 562 | 0.000 |
Why?
| | Research Design | 1 | 1997 | 1134 | 0.000 |
Why?
| | Lymphocyte Cooperation | 1 | 1990 | 50 | 0.000 |
Why?
| | Receptors, Lymphocyte Homing | 1 | 1990 | 15 | 0.000 |
Why?
| | Thymectomy | 1 | 1990 | 15 | 0.000 |
Why?
| | Antilymphocyte Serum | 1 | 1990 | 57 | 0.000 |
Why?
| | Antigens, Surface | 1 | 1990 | 155 | 0.000 |
Why?
| | Rabbits | 1 | 1990 | 651 | 0.000 |
Why?
| | Infectious Bovine Rhinotracheitis | 1 | 1989 | 1 | 0.000 |
Why?
| | Phorbol Esters | 1 | 1989 | 13 | 0.000 |
Why?
| | Ionomycin | 1 | 1989 | 22 | 0.000 |
Why?
| | Ethers | 1 | 1989 | 18 | 0.000 |
Why?
| | Kidney | 1 | 1997 | 1498 | 0.000 |
Why?
| | Isoantigens | 1 | 1988 | 17 | 0.000 |
Why?
| | Cell-Free System | 1 | 1988 | 53 | 0.000 |
Why?
| | Immunotherapy | 1 | 1994 | 667 | 0.000 |
Why?
| | Surveys and Questionnaires | 1 | 2000 | 6070 | 0.000 |
Why?
| | Breast Neoplasms | 1 | 1997 | 2373 | 0.000 |
Why?
| | Models, Biological | 1 | 1988 | 1815 | 0.000 |
Why?
|
|
Weinberg's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|